pivalyloxymethyl butyrate has been researched along with daunorubicin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Honma, Y; Kasukabe, T; Rephaeli, A | 1 |
| Honma, Y; Kasukabe, T; Niitsu, N; Okabe-Kado, J; Umeda, M; Yamamoto-Yamaguchi, Y; Yokoyama, A | 1 |
2 other study(ies) available for pivalyloxymethyl butyrate and daunorubicin
| Article | Year |
|---|---|
An anti-cancer derivative of butyric acid (pivalyloxmethyl buterate) and daunorubicin cooperatively prolong survival of mice inoculated with monocytic leukaemia cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Butyrates; Cell Differentiation; Cell Division; Daunorubicin; Drug Screening Assays, Antitumor; Female; Humans; Leukemia, Myeloid; Mice; Mice, Inbred Strains; Neoplasm Transplantation; Survival Analysis; Tumor Cells, Cultured | 1997 |
Anticancer derivative of butyric acid (Pivalyloxymethyl butyrate) specifically potentiates the cytotoxicity of doxorubicin and daunorubicin through the suppression of microsomal glycosidic activity.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Biological Transport; Butyrates; Cell Cycle; Cell Division; Daunorubicin; DNA; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Glycoside Hydrolases; Humans; Lung Neoplasms; Lymphoma; Microsomes; Oligonucleotides, Antisense; Structure-Activity Relationship; Tumor Cells, Cultured | 2000 |